Safety, tolerability, pharmacokinetics and pharmacodynamics of the oral cyclin-dependent kinase inhibitor AZD5438 when administered at intermittent and continuous dosing schedules in patients with advanced solid tumours

Annals of Oncology

Volumn 21, Issue 4, 2009, Pages 884-894

  Boss, D S ^a   Schwartz, G K ^b   Middleton, M R ^c   Amakye, D D ^d   Swaisland, H ^d   Midgley, R S ^c   Ranson, M ^e   Danson, S ^f   Calvert, H ^g   Plummer, R ^g   Morris, C ^d   Carvajal, R D ^b   Chirieac, L R ^h,i   Schellens, J H M ^a   Shapiro, G I ^h,i,j  

^a ANTONI VAN LEEUWENHOEK HOSPITAL   (Netherlands)

^b MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^c OXFORD UNIVERSITY HOSPITALS NHS FOUNDATION TRUST   (United Kingdom)

^d ASTRAZENECA   (United Kingdom)

^e CHRISTIE HOSPITAL   (United Kingdom)

^f UNIVERSITY OF MANCHESTER   (United Kingdom)

^g NEWCASTLE GENERAL HOSPITAL   (United Kingdom)

^h BRIGHAM AND WOMEN S HOSPITAL   (United States)

ⁱ HARVARD MEDICAL SCHOOL   (United States)

^j DANA FARBER CANCER INSTITUTE   (United States)

more..

Author keywords

AZD5438; Cyclin dependent kinase inhibitor; Hair follicle analysis; Pharmacodynamics

Indexed keywords

AZD 5438; CYCLIN DEPENDENT KINASE INHIBITOR; UNCLASSIFIED DRUG;

ABDOMINAL PAIN; ACUTE KIDNEY FAILURE; ADULT; AGED; ANOREXIA; AREA UNDER THE CURVE; ARTICLE; BACKACHE; BREAST CANCER; CLINICAL TRIAL; COLORECTAL CARCINOMA; CONSTIPATION; COUGHING; CREATININE BLOOD LEVEL; DEHYDRATION; DIAPHORESIS; DIARRHEA; DIZZINESS; DOSE RESPONSE; DRUG DOSE ESCALATION; DRUG FATALITY; DRUG FEVER; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSPEPSIA; DYSPNEA; EDEMA; ELECTROLYTE BLOOD LEVEL; ESOPHAGUS CARCINOMA; FATIGUE; FEMALE; HEART MUSCLE ISCHEMIA; HUMAN; HUMAN CELL; HUMAN TISSUE; LETHARGY; LEUKOCYTE COUNT; LIPOSARCOMA; LIVER METASTASIS; MAJOR CLINICAL STUDY; MALE; MAXIMUM PLASMA CONCENTRATION; MULTICENTER STUDY; NAUSEA AND VOMITING; PERICARDITIS; PHARMACODYNAMICS; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; RHINOPHARYNGITIS; SIDE EFFECT; SINGLE DRUG DOSE; SODIUM BLOOD LEVEL; SOLID TUMOR; TACHYCARDIA; TIME TO MAXIMUM PLASMA CONCENTRATION; UREA BLOOD LEVEL; URINE RETENTION; VATER PAPILLA CARCINOMA; WEAKNESS;

EID: 77951944979     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdp377     Document Type: Article

References (24)

1. Reed SI. Control of the G1/S transition. Cancer Surv 1997; 29: 7-23.
2. Lundberg AS, Weinberg RA. Functional inactivation of the retinoblastoma protein requires sequential modification by at least two distinct cyclin-cdk complexes. Mol Cell Biol 1998; 18: 753-761.
3. Harbour JW, Luo RX, Dei Santi A et al. Cdk phosphorylation triggers sequential intramolecular interactions that progressively block Rb functions as cells move through G1. Cell 1999; 98: 859-869.
4. Pines J. The cell cycle kinases. Semin Cancer Biol 1994; 5: 305-313.
5. Sherr CJ. Cancer cell cycles. Science 1996; 274: 1672-1677.
6. Shapiro GI. Cyclin-dependent kinase pathways as targets for cancer treatment. J Clin Oncol 2006; 24: 1770-1783.
7. Schwartz GK, Shah MA. Targeting the cell cycle: a new approach to cancer therapy. J Clin Oncol 2005; 23: 9408-9421.
8. Wheeler C, Stephens T, Byth K. Novel approaches in oncology at AstraZeneca. Eur J Cancer Suppl 2003; 1: 3-8.
9. Cai D, Byth KF, Shapiro GI. AZ703, an imidazo[1,2-a]pyridine inhibitor of cyclin dependent kinases 1 and 2, induces E2F-1-dependent apoptosis enhanced by depletion of cyclin-dependent kinase 9. Cancer Res 2006; 66: 435-444.
10. Byth KF, Geh C, Forder CL et al. The cellular phenotype of AZ703, a novel selective imidazo[1,2-a]pyridine cyclin-dependent kinase inhibitor. Mol Cancer Ther 2006; 5: 655-664.
11. Cai D, Latham VM Jr, Zhang X, Shapiro GI. Combined depletion of cell cycle and transcriptional cyclin-dependent kinase activities induces apoptosis in cancer cells. Cancer Res 2006; 66: 9270-9280.
12. Camidge DR, Smethurst D, Growcott J et al. A first-in-man phase I tolerability and pharmacokinetic study of the cyclin-dependent kinase-inhibitor AZD5438 in healthy male volunteers. Cancer Chemother Pharmacol 2007; 60: 391-398.
13. Camidge DR, Pemberton M, Growcott J et al. A phase I pharmacodynamic study of the effects of the cyclin-dependent kinase-inhibitor AZD5438 on cell cycle markers within the buccal mucosa, plucked scalp hairs and peripheral blood mononucleocytes of healthy male volunteers. Cancer Chemother Pharmacol 2007; 60: 479-488.
14. Therasse P, Arbuck SG, Eisenhauer EA et al. New guidelines to evaluate the response to treatment in solid tumors. J Natl Cancer Inst 2000; 92: 205-216.
15. Haddad RI, Weinstein LJ, Wieczorek TJ et al. A phase II clinical and pharmacodynamic study of E7070 in patients with metastatic, recurrent, or refractory squamous cell carcinoma of the head and neck: modulation of retinoblastoma protein phosphorylation by a novel chloroindolyl sulfonamide cell cycle inhibitor. Clin Cancer Res 2004; 10: 4680-4687.
16. Loda M, Cukor B, Tam SW et al. Increased proteasome-dependent degradation of the cyclin-dependent kinase inhibitor p27 in aggressive colorectal carcinomas. Nature Med 1997; 3: 231-234.
17. Hsieh WS, Soo R, Peh BK et al. Pharmacodynamic effects of seliciclib, an orally administered cell cycle modulator, in undifferentiated nasopharyngeal cancer. Clin Cancer Res 2009; 15: 1435-1442.
18. Stadler WM, Vogelzang NJ, Amato R et al. Flavopiridol, a novel cyclin-dependent kinase inhibitor, in metastatic renal cancer: a University of Chicago phase II consortium study. J Clin Oncol 2000; 18: 371-375.
19. George S, Kasimis BS, Cogswell J et al. Phase I study of flavopiridol in combination with paclitaxel and carboplatin in patients with non-small-cell lung cancer. Clin Lung Cancer 2008; 9: 160-165.
20. Bible KC, Lensing JL, Nelson SA et al. Phase 1 trial of flavopiridol combined with cisplatin or carboplatin in patients with advanced malignancies with the assessment of pharmacokinetic and pharmacodynamic end points. Clin Cancer Res 2005; 11: 5935-5941.
21. Zhang GJ, Safran M, Wei W et al. Bioluminescent imaging of Cdk2 inhibition in vivo. Nat Med 2004; 10: 643-648.
22. Kitagawa M, Higashi H, Jung HK et al. The consensus motif for phosphorylation by cyclin D1-cdk4 is different from that for phosphorylation by cyclin A/E-cdk2. EMBO J 1996; 15: 7060-7069.
23. Zarkowska T, Mittnacht S. Differential phosphorylation of the retinoblastoma proteinby G1/Scyclin-dependent kinases.J Biol Chem 1997; 272:12738-12746.
24. Brantley MA, Harbour JW. Inactivation of retinoblastoma protein in uveal melanoma by phosphorylation of sites in the COOH-terminal region. Cancer Res 2000; 60: 4320-4323.